Sign in or create an account to add this stock to your watchlist.
About NuVasive (NASDAQ:NUVA)
NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800
Debt
Debt-to-Equity Ratio0.77
Current Ratio2.41
Quick Ratio1.30
Price-To-Earnings
Trailing P/E Ratio26.21
Forward P/E Ratio20.43
P/E Growth1.36
Sales & Book Value
Annual Sales$1.03 billion
Price / Sales2.49
Cash Flow$4.7405 per share
Price / Cash10.56
Book Value$14.87 per share
Price / Book3.37
Profitability
EPS (Most Recent Fiscal Year)$1.91
Net Income$83 million
Net Margins4.14%
Return on Equity13.14%
Return on Assets6.11%
Miscellaneous
Employees2,600
Outstanding Shares51,260,000
NuVasive (NASDAQ:NUVA) Frequently Asked Questions
What is NuVasive's stock symbol?
NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
How will NuVasive's stock buyback program work?
NuVasive announced that its board has authorized a share buyback plan on Wednesday, October 25th 2017, which allows the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Shares buyback plans are often a sign that the company's board of directors believes its stock is undervalued.
How were NuVasive's earnings last quarter?
NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings data on Tuesday, May, 1st. The medical device company reported $0.39 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.45 by $0.06. The medical device company had revenue of $260.50 million for the quarter, compared to analysts' expectations of $259.43 million. NuVasive had a return on equity of 13.14% and a net margin of 4.14%. The business's revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.37 EPS. View NuVasive's Earnings History.
When is NuVasive's next earnings date?
What guidance has NuVasive issued on next quarter's earnings?
NuVasive updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $2.44-2.47 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.46. The company issued revenue guidance of $1.095-1.105 billion, compared to the consensus revenue estimate of $1.10 billion.
What price target have analysts set for NUVA?
16 equities research analysts have issued twelve-month price targets for NuVasive's shares. Their forecasts range from $47.00 to $90.00. On average, they expect NuVasive's share price to reach $66.5333 in the next twelve months. View Analyst Ratings for NuVasive.
What are Wall Street analysts saying about NuVasive stock?
Here are some recent quotes from research analysts about NuVasive stock:
- 1. Needham & Company LLC analysts commented, "NUVA’s 1Q18 revenue beat and EPS missed consensus. Management reiterated its 2018 revenue and EPS guidance. Organic revenue growth improved to 2% in 1Q18 from 0% in 4Q17 as US Spinal Hardware and biologics growth improved. NUVA’s revenue guidance requires it to accelerate its revenue growth; we believe that it can do this given new products, easing comps, and stabilization of biologics. And its EPS guidance requires a substantial improvement in its gross and operating margin; we believe it can do this with improvements in its new manufacturing plant and SG&A leverage. Unfortunately, both the revenue and margin ramps are likely to continue to make NUVA a show me" story despite its discount P/E multiple." (5/2/2018)
- 2. According to Zacks Investment Research, "NuVasive has underperformed its industry over the past six months. The company's U.S. business has been delivering dull performance with softness in both U.S. Spinal Hardware and U.S. Surgical Support businesses. However, solid performance of the international business with more than 20% growth for the fifth consecutive quarter buoys optimism. The company’s expectation to higher adjusted operating profit margin of at least 100 bps in 2018 reflects its focus on operational efficiencies and in-house manufacturing facility. Moreover, we are upbeat about the recently-completed buyout of SafePassage. Per NuVasive, the acquisition will strengthen the company's intraoperative neuromonitoring business line. The consolidated giant is expected to deliver services to more than 1,000 customers and 3,000 surgeons." (5/1/2018)
Are investors shorting NuVasive?
NuVasive saw a decline in short interest in April. As of April 30th, there was short interest totalling 5,124,933 shares, a decline of 23.8% from the April 13th total of 6,729,507 shares. Based on an average daily trading volume, of 741,551 shares, the short-interest ratio is presently 6.9 days. Approximately 10.1% of the company's shares are short sold.
Who are some of NuVasive's key competitors?
Some companies that are related to NuVasive include Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Cantel Medical (CMD), Insulet (PODD), Globus Medical (GMED), Haemonetics (HAE), Merit Medical Systems (MMSI), NovoCure (NVCR), Nevro (NVRO), iRhythm (IRTC), Mazor Robotics (MZOR), Luminex (LMNX) and Glaukos (GKOS).
Who are NuVasive's key executives?
NuVasive's management team includes the folowing people:
- Mr. Gregory T. Lucier, Chairman & CEO (Age 54)
- Mr. Matthew W. Link, Exec. VP of Strategy, Technology & Corp. Devel. (Age 43)
- Mr. Jason Marshall Hannon, Former Pres & COO (Age 46)
- Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 51)
- Mr. Jereme Sylvain, Chief Accounting Officer (Age 38)
Has NuVasive been receiving favorable news coverage?
News articles about NUVA stock have been trending positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. NuVasive earned a news impact score of 0.36 on Accern's scale. They also gave news headlines about the medical device company an impact score of 47.59 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are NuVasive's major shareholders?
NuVasive's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Champlain Investment Partners LLC (6.13%), Fisher Asset Management LLC (2.49%), Dimensional Fund Advisors LP (2.31%), Eagle Asset Management Inc. (2.19%), OppenheimerFunds Inc. (1.72%) and Northern Trust Corp (1.53%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.
Which major investors are selling NuVasive stock?
NUVA stock was sold by a variety of institutional investors in the last quarter, including State of Tennessee Treasury Department, OppenheimerFunds Inc., Scout Investments Inc., PNC Financial Services Group Inc., Eos Focused Equity Management L.P., Stevens Capital Management LP, Fisher Asset Management LLC and Eagle Asset Management Inc.. View Insider Buying and Selling for NuVasive.
Which major investors are buying NuVasive stock?
NUVA stock was purchased by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Rock Springs Capital Management LP, Victory Capital Management Inc., Champlain Investment Partners LLC, Hood River Capital Management LLC, Mesirow Financial Investment Management Equity Management, Dimensional Fund Advisors LP and Fort Washington Investment Advisors Inc. OH. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.
How do I buy shares of NuVasive?
Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuVasive's stock price today?
One share of NUVA stock can currently be purchased for approximately $50.06.
How big of a company is NuVasive?
NuVasive has a market capitalization of $2.57 billion and generates $1.03 billion in revenue each year. The medical device company earns $83 million in net income (profit) each year or $1.91 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.
How can I contact NuVasive?
NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]
MarketBeat Community Rating for NuVasive (NUVA)
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
NuVasive (NASDAQ:NUVA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
16 Wall Street analysts have issued ratings and price targets for NuVasive in the last 12 months. Their average twelve-month price target is $66.5333, suggesting that the stock has a possible upside of 32.91%. The high price target for NUVA is $90.00 and the low price target for NUVA is $47.00. There are currently 6 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.63 | 2.69 | 2.75 | 2.76 |
| Ratings Breakdown: | 0 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $66.5333 | $66.80 | $72.3333 | $72.3333 |
| Price Target Upside: | 32.91% upside | 24.53% upside | 48.01% upside | 27.50% upside |
NuVasive (NASDAQ:NUVA) Consensus Price Target History
NuVasive (NASDAQ:NUVA) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
NuVasive (NASDAQ:NUVA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
NuVasive (NASDAQ NUVA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.20%
NuVasive (NASDAQ NUVA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/6/2018 | Gregory T Lucier | CEO | Buy | 6,000 | $50.30 | $301,800.00 | |  |
| 3/1/2018 | Gregory T Lucier | CEO | Buy | 6,000 | $48.57 | $291,420.00 | | |
| 8/29/2017 | Gregory T Lucier | CEO | Buy | 2,000 | $61.52 | $123,040.00 | | |
| 8/18/2017 | Lesley H. Howe | Director | Sell | 3,970 | $64.64 | $256,620.80 | | |
| 8/17/2017 | Gregory T Lucier | CEO | Buy | 5,000 | $66.22 | $331,100.00 | | |
| 8/1/2017 | Peter Michael Leddy | EVP | Buy | 7,850 | $63.88 | $501,458.00 | | |
| 3/8/2017 | Jason Hannon | Insider | Sell | 24,840 | $74.22 | $1,843,624.80 | | |
| 2/14/2017 | Lesley H. Howe | Director | Sell | 6,049 | $73.26 | $443,149.74 | | |
| 12/12/2016 | Matthew Link | Insider | Sell | 10,303 | $67.99 | $700,500.97 | | |
| 11/4/2016 | Michael D Ohalleran | Director | Buy | 4,200 | $58.26 | $244,692.00 | | |
| 11/2/2016 | Patrick Miles | Director | Buy | 16,967 | $58.97 | $1,000,543.99 | | |
| 11/1/2016 | Patrick Miles | Director | Buy | 16,667 | $59.00 | $983,353.00 | | |
| 10/31/2016 | Joan Stafslien | EVP | Buy | 5,000 | $59.68 | $298,400.00 | | |
| 10/31/2016 | Michael D Ohalleran | Director | Buy | 4,205 | $59.47 | $250,071.35 | | |
| 8/23/2016 | Jason Hannon | EVP | Sell | 2,625 | $64.80 | $170,100.00 | | |
| 8/2/2016 | Jason Hannon | EVP | Sell | 11,184 | $62.70 | $701,236.80 | | |
| 8/2/2016 | Lesley H. Howe | Director | Sell | 3,602 | $62.44 | $224,908.88 | | |
| 7/20/2016 | Jason Hannon | EVP | Sell | 2,920 | $62.80 | $183,376.00 | | |
| 6/16/2016 | Jason Hannon | EVP | Sell | 14,534 | $57.57 | $836,722.38 | 37,616 | |
| 1/6/2016 | Patrick Miles | COO | Sell | 10,723 | $54.03 | $579,363.69 | 31,646 | |
| 12/16/2015 | Patrick Miles | COO | Sell | 9,127 | $52.56 | $479,715.12 | 31,646 | |
| 12/7/2015 | Quentin S Blackford | CFO | Sell | 15,000 | $51.10 | $766,500.00 | 2,599 | |
| 12/3/2015 | Patrick Miles | COO | Sell | 5,873 | $52.51 | $308,391.23 | 40,773 | |
| 11/2/2015 | Patrick Miles | COO | Sell | 15,000 | $48.12 | $721,800.00 | 32,627 | |
| 10/5/2015 | Matthew Link | insider | Sell | 1,714 | $50.72 | $86,934.08 | 53,089 | |
| 10/3/2015 | Quentin S Blackford | CFO | Sell | 5,000 | $36.30 | $181,500.00 | | |
| 10/1/2015 | Patrick Miles | COO | Sell | 15,000 | $48.10 | $721,500.00 | 47,627 | |
| 9/8/2015 | Russell Powers | EVP | Sell | 5,806 | $51.64 | $299,821.84 | 62,024 | |
| 9/2/2015 | Jason Hannon | EVP | Sell | 11,962 | $52.02 | $622,263.24 | 18,565 | |
| 9/1/2015 | Patrick Miles | COO | Sell | 15,000 | $52.03 | $780,450.00 | 62,627 | |
| 8/31/2015 | Patrick Miles | COO | Sell | 15,000 | $53.34 | $800,100.00 | 62,627 | |
| 7/20/2015 | Jason Hannon | EVP | Sell | 15,000 | $49.60 | $744,000.00 | | |
| 6/15/2015 | Gregory T Lucier | CEO | Buy | 4,491 | $49.49 | $222,259.59 | | |
| 6/12/2015 | Gregory T Lucier | CEO | Buy | 8,000 | $50.10 | $400,800.00 | | |
| 6/10/2015 | Gregory T Lucier | CEO | Buy | 10,000 | $49.10 | $491,000.00 | | |
| 6/8/2015 | Gregory T Lucier | CEO | Buy | 10,000 | $49.26 | $492,600.00 | | |
| 6/4/2015 | Gregory T Lucier | CEO | Buy | 10,000 | $49.71 | $497,100.00 | | |
| 6/2/2015 | Gregory T Lucier | CEO | Buy | 8,000 | $49.96 | $399,680.00 | | |
| 6/2/2015 | Patrick Miles | COO | Sell | 4,194 | $49.47 | $207,477.18 | | |
| 5/29/2015 | Jack R Blair | Director | Sell | 3,703 | $50.16 | $185,742.48 | | |
| 5/28/2015 | Gregory T Lucier | CEO | Buy | 34,000 | $49.25 | $1,674,500.00 | | |
| 5/28/2015 | Russell Powers | EVP | Sell | 8,042 | $49.00 | $394,058.00 | | |
| 5/19/2015 | Patrick Miles | COO | Sell | 15,000 | $47.52 | $712,800.00 | | |
| 5/1/2015 | Russell Powers | EVP | Sell | 11,881 | $45.21 | $537,140.01 | | |
| 4/24/2015 | Russell Powers | EVP | Sell | 3,888 | $44.07 | $171,344.16 | | |
| 3/13/2015 | Patrick Miles | COO | Sell | 7,920 | $45.52 | $360,518.40 | | |
| 3/9/2015 | Alexis V Lukianov | CEO | Sell | 5,313 | $44.82 | $238,128.66 | | |
| 3/3/2015 | Matthew Link | Insider | Sell | 7,500 | $44.46 | $333,450.00 | | |
| 3/2/2015 | Jason Hannon | EVP | Sell | 5,085 | $45.06 | $229,130.10 | | |
| 2/9/2015 | Alexis V Lukianov | CEO | Sell | 5,454 | $46.10 | $251,429.40 | | |
| 2/5/2015 | Matthew Link | Insider | Sell | 4,078 | $45.77 | $186,650.06 | | |
| 2/3/2015 | Patrick Miles | COO | Sell | 15,000 | $45.53 | $682,950.00 | | |
| 1/28/2015 | Keith Valentine | COO | Sell | 6,970 | $46.96 | $327,311.20 | | |
| 1/12/2015 | Alexis V Lukianov | CEO | Sell | 7,452 | $49.69 | $370,289.88 | | |
| 1/5/2015 | Jason Hannon | EVP | Sell | 12,117 | $46.82 | $567,317.94 | | |
| 1/5/2015 | Patrick Miles | Insider | Sell | 15,000 | $46.61 | $699,150.00 | | |
| 12/30/2014 | Jason Hannon | EVP | Sell | 15,000 | $47.63 | $714,450.00 | | |
| 12/29/2014 | Jason Hannon | EVP | Sell | 3,146 | $47.57 | $149,655.22 | | |
| 12/24/2014 | Patrick Miles | Insider | Sell | 15,000 | $47.52 | $712,800.00 | | |
| 12/19/2014 | Keith Valentine | COO | Sell | 5,893 | $47.78 | $281,567.54 | | |
| 12/1/2014 | Keith Valentine | COO | Sell | 2,500 | $43.66 | $109,150.00 | | |
| 11/19/2014 | Keith Valentine | COO | Sell | 5,582 | $43.32 | $241,812.24 | | |
| 11/19/2014 | Quentin S Blackford | CFO | Sell | 7,698 | $43.41 | $334,170.18 | | |
| 11/7/2014 | Alexis V Lukianov | CEO | Sell | 25,000 | $41.40 | $1,035,000.00 | | |
| 11/3/2014 | Keith Valentine | COO | Sell | 2,500 | $40.61 | $101,525.00 | | |
| 10/2/2014 | Keith Valentine | COO | Sell | 2,500 | $35.00 | $87,500.00 | | |
| 9/2/2014 | Keith Valentine | COO | Sell | 2,500 | $35.14 | $87,850.00 | | |
| 8/1/2014 | Keith Valentine | COO | Sell | 2,500 | $37.11 | $92,775.00 | | |
| 8/1/2014 | Michael Lambert | CFO | Sell | 4,010 | $37.11 | $148,811.10 | | |
| 7/30/2014 | Jason Hannon | EVP | Sell | 5,000 | $39.00 | $195,000.00 | | |
| 7/10/2014 | Russell Powers | EVP | Sell | 3,200 | $33.43 | $106,976.00 | | |
| 7/1/2014 | Keith Valentine | COO | Sell | 2,500 | $35.65 | $89,125.00 | | |
| 7/1/2014 | Michael Lambert | CFO | Sell | 23,225 | $35.48 | $824,023.00 | | |
| 6/20/2014 | Keith Valentine | COO | Sell | 5,000 | $35.00 | $175,000.00 | | |
| 6/20/2014 | Russell Powers | EVP | Sell | 9,526 | $35.00 | $333,410.00 | | |
| 5/5/2014 | Robert Hunt | Director | Sell | 20,000 | $34.25 | $685,000.00 | 34,500 | |
| 5/2/2014 | Michael Lambert | CFO | Sell | 13,096 | $33.07 | $433,084.72 | 51,695 | |
| 4/1/2014 | Keith Valentine | COO | Sell | 2,500 | $38.41 | $96,025.00 | 88,985 | |
| 3/11/2014 | Peter Farrell | Director | Sell | 48,000 | $36.88 | $1,770,240.00 | 6,794 | |
| 1/21/2014 | Jason Hannon | EVP | Sell | 10,095 | $36.60 | $369,477.00 | 8,899 | |
| 1/16/2014 | Keith Valentine | COO | Sell | 20,000 | $37.96 | $759,200.00 | 44,226 | |
| 1/7/2014 | Alexis Lukianov | CEO | Sell | 34,217 | $34.29 | $1,173,300.93 | 55,740 | |
| 1/7/2014 | Craig Hunsaker | SVP | Sell | 4,980 | $35.00 | $174,300.00 | 21,142 | |
| 12/30/2013 | Craig Hunsaker | SVP | Sell | 4,275 | $32.10 | $137,227.50 | 24,980 | |
| 12/23/2013 | Michael Lambert | CFO | Sell | 17,091 | $32.49 | $555,286.59 | 13,096 | |
| 11/7/2013 | Alexis Lukianov | CEO | Sell | 5,000 | $31.45 | $157,250.00 | 72,827 | |
| 10/30/2013 | Jason Hannon | EVP | Sell | 2,334 | $28.90 | $67,452.60 | | |
| 10/30/2013 | Patrick Miles | Insider | Sell | 21,223 | $31.10 | $660,035.30 | | |
| 10/28/2013 | Patrick Miles | Insider | Sell | 7,331 | $25.72 | $188,553.32 | | |
| 10/21/2013 | Russell Powers | VP | Sell | 12,500 | $25.39 | $317,375.00 | | |
| 10/11/2013 | Jason Hannon | EVP | Sell | 1,000 | $26.00 | $26,000.00 | 19,991 | |
| 10/7/2013 | Jason Hannon | EVP | Sell | 8,705 | $23.99 | $208,832.95 | 19,991 | |
| 10/7/2013 | Michael Lambert | CFO | Sell | 15,442 | $24.04 | $371,225.68 | 30,187 | |
| 8/6/2013 | Richard Treharne III | Director | Buy | 2,000 | $23.26 | $46,520.00 | | |
| 7/12/2013 | Craig E Hunsaker | SVP | Sell | 2,000 | $27.00 | $54,000.00 | | |
| 7/8/2013 | Alexis V Lukianov | CEO | Sell | 5,000 | $25.74 | $128,700.00 | | |
| 7/1/2013 | Keith Valentine | COO | Sell | 1,698 | $25.00 | $42,450.00 | | |
| 5/13/2013 | Alexis V Lukianov | CEO | Sell | 7,500 | $22.71 | $170,325.00 | | |
| 5/8/2013 | Peter Michael Leddy | Director | Buy | 2,400 | $22.24 | $53,376.00 | | |
| 5/7/2013 | Alexis V Lukianov | CEO | Sell | 12,500 | $22.11 | $276,375.00 | | |
(Data available from 1/1/2013 forward)
NuVasive (NASDAQ NUVA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Nuvasive SpineTRACK Registry Reaches Significant Enrollment Milestone Of 10000 Patients
www.prnewswire.com - May 23 at 8:52 AM |
 | Nuvasive SpineTRACK Registry Reaches Significant Enrollment Milestone Of 10,000 Patients
finance.yahoo.com - May 23 at 8:52 AM |
 | K2M Disrupting The Market, Growing, And Still Undervalued
seekingalpha.com - May 22 at 4:41 PM |
| NuVasive Not Getting, Or Deserving, The Benefit Of The Doubt Yet
seekingalpha.com - May 22 at 8:54 AM |
| NuVasive PRECICE STRYDE™ System Used In First Patient For Stature Lengthening By International Limb ...
www.prnewswire.com - May 22 at 8:54 AM |
| NuVasive PRECICE STRYDE™ System Used In First Patient For Stature Lengthening By International Limb Lengthening Expert
finance.yahoo.com - May 22 at 8:54 AM |
 | NuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $276.05 Million
www.americanbankingnews.com - May 22 at 4:02 AM |
| Brokerages Anticipate NuVasive, Inc. (NUVA) Will Post Earnings of $0.58 Per Share
www.americanbankingnews.com - May 20 at 11:16 AM |
| NuVasive Target of Unusually Large Options Trading (NUVA)
www.americanbankingnews.com - May 18 at 6:46 AM |
| NuVasive Sponsors SOLAS 2018, Hosts Workshop On Latest Lateral Innovations
www.prnewswire.com - May 16 at 4:54 PM |
| NuVasive (NUVA) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - May 16 at 10:30 AM |
 | NuVasive To Present At Bank Of America Conference; Webcast At 11:40 AM ET
www.nasdaq.com - May 15 at 5:12 PM |
| NuVasive, Inc. (NUVA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 13 at 7:52 PM |
| NuVasive, Inc. (NUVA) Short Interest Down 23.8% in April
www.americanbankingnews.com - May 13 at 1:40 AM |
| NuVasive To Present At The Bank of America Merrill Lynch 2018 Healthcare Conference
finance.yahoo.com - May 9 at 4:53 PM |
| NuVasive Unveils Newest Additions To Early Onset Scoliosis Portfolio At POSNA Annual Meeting
finance.yahoo.com - May 8 at 4:52 PM |
| NuVasive, Inc. (NUVA) to Post Q2 2018 Earnings of $0.61 Per Share, William Blair Forecasts
www.americanbankingnews.com - May 7 at 1:54 AM |
| NuVasive, Inc. (NUVA) to Post Q4 2018 Earnings of $0.84 Per Share, William Blair Forecasts
www.americanbankingnews.com - May 4 at 8:37 AM |
| Q2 2018 Earnings Estimate for NuVasive, Inc. (NUVA) Issued By Leerink Swann
www.americanbankingnews.com - May 4 at 7:31 AM |
| Q2 2018 Earnings Estimate for NuVasive, Inc. Issued By Jefferies Group (NUVA)
www.americanbankingnews.com - May 4 at 7:31 AM |
| NuVasive, Inc. (NUVA) Expected to Announce Quarterly Sales of $277.17 Million
www.americanbankingnews.com - May 4 at 1:54 AM |
| Brokers Set Expectations for NuVasive, Inc.'s FY2019 Earnings (NUVA)
www.americanbankingnews.com - May 3 at 9:57 AM |
| NuVasive, Inc. (NUVA) to Post Q3 2018 Earnings of $0.62 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 3 at 9:19 AM |
| Analysts Issue Forecasts for NuVasive, Inc.'s Q2 2018 Earnings (NUVA)
www.americanbankingnews.com - May 3 at 8:06 AM |
| NuVasive, Inc. (NUVA) Expected to Announce Earnings of $0.59 Per Share
www.americanbankingnews.com - May 2 at 11:16 PM |
| ValuEngine Lowers NuVasive (NUVA) to Strong Sell
www.americanbankingnews.com - May 2 at 11:11 PM |
| NuVasive (NUVA) Downgraded by BMO Capital Markets to Market Perform
www.americanbankingnews.com - May 2 at 11:10 AM |
| NuVasive's (NUVA) Buy Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - May 2 at 10:47 AM |
 | The Key Reason NuVasive Lost Money Last Quarter
www.fool.com - May 2 at 9:19 AM |
| NuVasive (NUVA) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 9:01 AM |
 | BRIEF-NuVasive Reports Q1 GAAP Loss Per Share Of $0.53
www.reuters.com - May 2 at 9:01 AM |
 | NuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In Line
www.zacks.com - May 2 at 9:01 AM |
| NuVasive, Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 2 at 9:01 AM |
| Edited Transcript of NUVA earnings conference call or presentation 1-May-18 8:30pm GMT
finance.yahoo.com - May 2 at 9:00 AM |
| NuVasive (NUVA) Given "Buy" Rating at BTIG Research
www.americanbankingnews.com - May 2 at 8:50 AM |
| NuVasive (NUVA) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 1 at 9:10 PM |
| NuVasive (NUVA) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 1 at 6:32 PM |
| Earnings Reaction History: NuVasive, Inc., 44.4% Follow-Through Indicator, 5.9% Sensitive
www.nasdaq.com - May 1 at 4:42 PM |
| NuVasive Q1 18 Earnings Conference Call At 4:30 PM ET
www.nasdaq.com - May 1 at 4:42 PM |
| NuVasive: 1Q Earnings Snapshot
finance.yahoo.com - May 1 at 4:42 PM |
| NuVasive Announces First Quarter 2018 Financial Results
www.prnewswire.com - May 1 at 4:10 PM |
| NuVasive (NUVA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 1 at 12:26 PM |
| NuVasive, Inc. (NUVA) Sees Large Growth in Short Interest
www.americanbankingnews.com - April 26 at 2:22 AM |
| NuVasive Sponsors AANS 2018, Hosts Workshops And Presentations On Latest Innovations
finance.yahoo.com - April 24 at 5:01 PM |
| NuVasive (NUVA) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - April 24 at 9:36 AM |
| NuVasive (NUVA) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 21 at 7:24 AM |
 | New Research: Key Drivers of Growth for NuVasive, Apptio, Apollo Investment, Uranium Energy, AECOM, and US ...
globenewswire.com - April 19 at 9:00 AM |
| Investors Purchase Large Volume of Put Options on NuVasive (NUVA)
www.americanbankingnews.com - April 19 at 8:32 AM |
| NuVasive, Inc. (NUVA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 18 at 7:24 PM |
| NuVasive, Inc. (NUVA) Expected to Announce Quarterly Sales of $260.48 Million
www.americanbankingnews.com - April 17 at 2:17 AM |
NuVasive (NASDAQ:NUVA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NuVasive (NASDAQ:NUVA) Income Statement, Balance Sheet and Cash Flow Statement
NuVasive (NASDAQ NUVA) Stock Chart for Saturday, May, 26, 2018
Loading chart…
